samedan logo
 
 
 
spacer
home > pmps > summer 2008 > polyethylene glycol purity
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Polyethylene Glycol Purity

One of the main challenges in the pharmaceutical industry is the ability to produce stable drug formulations. This is especially demanding as many active pharmaceutical ingredients (APIs) respond unstably to oxidation, moisture or pH. Generally, excipients are the major component of any given drug formulation. In the past, pharmaceutical excipients have been viewed as ‘inert’ ingredients that played an insignificant role in the stability of formulations containing APIs. This view is now changing as pharmaceutical formulators have gained a greater awareness of the importance of excipient purity. Excipient impurities can accelerate the degradation of the API as well as destabilising emulsions, causing skin and cellular irritation (1,2) and promoting gelatin cross-linking (3) in both soft gelatin and hard gelatin capsules.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
Nigel Langley, PhD, is currently Technical Director – Health Care for Croda Inc, Edison, New Jersey. He obtained a BSC Hons and PhD from the University of Hull, UK and then undertook a two-year Postdoctoral project (natural product synthesis) at Leeds University, UK. He joined Croda in 1984 and has held various technical positions in four Croda Companies. He spent three years as Technical Director of Croda Japan before joining Croda Inc (USA) in 2001. Nigel’s research interests are in lipid chemistry both for Pharmaceutical and Personal Care applications.

Karen H Chen is currently Marketing Manager of Health Care at Croda Inc (USA). She holds a Bachelors degree in Biology and Chemistry from Rutgers University and a Masters degree in Cosmetic Science from Fairleigh Dickinson University. She began her career in the cosmetic industry as a personal care formulator at Johnson & Johnson and a skin care formulator at Avon Products. She later moved into technical sales for Biosil Technologies and Wacker Chemical Corporation prior to her start at Croda Inc (USA) as the Marketing Manager of Skin Care and Makeup. Karen is active in the New York Chapter of the Society of Cosmetic Chemists (NYSCC) having held the positions of Treasurer and Photographer, a position she currently occupies. In addition she also serves on the NYSCC Supplier’s Day Committee and the NYSCC Scholarship Committee.

spacer
Nigel Langley
spacer
spacer
spacer
Karen H Chen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ROUSSELOT INTRODUCES X-PURE® GelMA FOR TRANSLATIONAL MEDICINE

Irving, United States [03 June 2020] — Rousselot, a Darling Ingredients brand and the global leader of collagen-based solutions, takes on the digital challenge and introduces X-Pure® GelMA at Bio Digital 2020. The first GMP-ready range of gelatin methacryloyl (GelMA) biomaterials suitable for preclinical and clinical applications, X-Pure® GelMA is part of the X-Pure portfolio of ultra-pure gelatins and collagens, suitable for use as biomaterials in 3D bioprinting, tissue engineering, and regenerative medicine.
More info >>

White Papers

Financial implications of off-site visits in clinical research, perception versus reality

Illingworth Research

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement